You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlogliptin
Accession NumberDB06203
TypeSmall Molecule
GroupsApproved
Description

Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.

Structure
Thumb
Synonyms
Alogliptina
Alogliptine
Alogliptinum
SYR-322
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alogliptintablet, film coated25 mg/1oralPerrigo New York Inc2016-04-08Not applicableUs
Alogliptintablet, film coated12.5 mg/1oralPerrigo New York Inc2016-04-08Not applicableUs
Alogliptintablet, film coated6.25 mg/1oralPerrigo New York Inc2016-04-08Not applicableUs
Nesinatablet6.25 mgoralTakeda Canada Inc2014-04-30Not applicableCanada
Nesinatablet, film coated6.25 mg/1oralTakeda Pharmaceuticals America, Inc.2013-01-25Not applicableUs
Nesinatablet, film coated25 mg/1oralTakeda Pharmaceuticals America, Inc.2013-01-25Not applicableUs
Nesinatablet, film coated12.5 mg/1oralTakeda Pharmaceuticals America, Inc.2013-01-25Not applicableUs
Nesinatablet25 mgoralTakeda Canada Inc2014-05-13Not applicableCanada
Nesinatablet12.5 mgoralTakeda Canada Inc2014-04-30Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Alogliptin and Metformin HydrochloridePerrigo New York Inc
Alogliptin and PioglitazonePerrigo New York Inc
KazanoTakeda Canada Inc
OseniTakeda Canada Inc
Salts
Name/CASStructureProperties
Alogliptin Benzoate
Thumb
  • InChI Key: KEJICOXJTRHYAK-XFULWGLBSA-N
  • Monoisotopic Mass: 461.206304377
  • Average Mass: 461.513
DBSALT000007
Categories
UNIIJHC049LO86
CAS number850649-61-5
WeightAverage: 339.3916
Monoisotopic: 339.169524941
Chemical FormulaC18H21N5O2
InChI KeyInChIKey=ZSBOMTDTBDDKMP-OAHLLOKOSA-N
InChI
InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
IUPAC Name
2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile
SMILES
CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylmethylamines
Direct ParentPhenylmethylamines
Alternative Parents
Substituents
  • Dialkylarylamine
  • Phenylmethylamine
  • Benzonitrile
  • Pyrimidone
  • Aminopyrimidine
  • 3-aminopiperidine
  • Pyrimidine
  • Piperidine
  • Hydropyrimidine
  • Heteroaromatic compound
  • Vinylogous amide
  • Urea
  • Tertiary amine
  • Lactam
  • Azacycle
  • Organoheterocyclic compound
  • Nitrile
  • Carbonitrile
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
PharmacodynamicsPeak inhibition of DPP-4 occurs within 2-3 hours after a single-dose administration to healthy subjects. The peak inhibition of DPP-4 exceeded 93% across doses of 12.5 mg to 800 mg. Inhibition of DPP-4 remained above 80% at 24 hours for doses greater than or equal to 25 mg. Alogliptin also demonstrated decreases in postprandial glucagon while increasing postprandial active GLP-1 levels compared to placebo over an 8-hour period following a standardized meal. Alogliptin does not affect the QTc interval.
Mechanism of actionAlogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.
Related Articles
AbsorptionThe pharmacokinetics of NESINA was also shown to be similar in healthy subjects and in patients with type 2 diabetes. When single, oral doses up to 800 mg in healthy subjects and type 2 diabetes patients are given, the peak plasma alogliptin concentration (median Tmax) occurred 1 to 2 hours after dosing. Accumulation of aloglipin is minimal. The absolute bioavailability of NESINA is approximately 100%. Food does not affect the absorption of alogliptin.
Volume of distribution

Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.

Protein bindingAlogliptin is 20% bound to plasma proteins.
Metabolism

Alogliptin does not undergo extensive metabolism. Two minor metabolites that were detected are N-demethylated alogliptin (<1% of parent compound) and N-acetylated alogliptin (<6% of parent compound). The N-demethylated metabolite is active and an inhibitor of DPP-4. The N-acetylated metabolite is inactive. Cytochrome enzymes that are involved with the metabolism of alogliptin are CYP2D6 and CYP3A4 but the extent to which this occurs is minimal. Approximately 10-20% of the dose is hepatically metabolized by cytochrome enzymes.

Route of eliminationRenal excretion (76%) and feces (13%). 60% to 71% of the dose is excreted as unchanged drug in the urine.
Half lifeTerminal half-life = 21 hours
Clearance

Renal clearance = 9.6 L/h (this value indicates some active renal tubular secretion);
Systemic clearance = 14.0 L/h.

ToxicityCommon adverse reactions (reported in ≥4% of patients treated with alogliptin 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache, and upper respiratory tract infection.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9942
Blood Brain Barrier+0.9738
Caco-2 permeable-0.5492
P-glycoprotein substrateSubstrate0.6453
P-glycoprotein inhibitor INon-inhibitor0.6811
P-glycoprotein inhibitor IINon-inhibitor0.9238
Renal organic cation transporterNon-inhibitor0.591
CYP450 2C9 substrateNon-substrate0.8003
CYP450 2D6 substrateNon-substrate0.7259
CYP450 3A4 substrateSubstrate0.5528
CYP450 1A2 substrateNon-inhibitor0.9169
CYP450 2C9 inhibitorNon-inhibitor0.8475
CYP450 2D6 inhibitorNon-inhibitor0.9038
CYP450 2C19 inhibitorNon-inhibitor0.8527
CYP450 3A4 inhibitorNon-inhibitor0.7608
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9363
Ames testNon AMES toxic0.5595
CarcinogenicityNon-carcinogens0.8887
BiodegradationNot ready biodegradable0.9931
Rat acute toxicity2.5603 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5507
hERG inhibition (predictor II)Inhibitor0.8389
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral12.5 mg
Tabletoral25 mg
Tabletoral6.25 mg
Tablet, film coatedoral12.5 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral6.25 mg/1
Tabletoral
Tablet, film coatedoral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5965584 No1996-06-192016-06-19Us
US6150383 No1996-06-192016-06-19Us
US6150384 No1996-06-192016-06-19Us
US6166042 No1996-06-192016-06-19Us
US6166043 No1996-06-192016-06-19Us
US6172090 No1996-06-192016-06-19Us
US6211205 No1996-06-192016-06-19Us
US6271243 No1996-06-192016-06-19Us
US6303640 No1996-08-092016-08-09Us
US6303661 No1997-04-242017-04-24Us
US6329404 No1996-06-192016-06-19Us
US6890898 No1999-02-022019-02-02Us
US7078381 No1999-02-022019-02-02Us
US7459428 No1999-02-022019-02-02Us
US7807689 No2008-06-272028-06-27Us
US8173663 No2005-03-152025-03-15Us
US8288539 No2005-03-152025-03-15Us
US8637079 No2009-06-042029-06-04Us
US8697125 No2009-01-222029-01-22Us
US8900638 No2009-05-242029-05-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySparingly soluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.58 mg/mLALOGPS
logP0.66ALOGPS
logP1.16ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)9.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area93.67 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity104.26 m3·mol-1ChemAxon
Polarizability35.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Kenji Nakamura, Kenichiro Kiyoshima, Junya Nomura, “SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE.” U.S. Patent US20100092551, issued April 15, 2010.

US20100092551
General References
  1. Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008 Mar;30(3):513-27. doi: 10.1016/j.clinthera.2008.03.005. [PubMed:18405789 ]
  2. Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008 Mar;30(3):499-512. doi: 10.1016/j.clinthera.2008.03.004. [PubMed:18405788 ]
  3. Golightly LK, Drayna CC, McDermott MT: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. doi: 10.2165/11632930-000000000-00000. [PubMed:22686547 ]
External Links
ATC CodesA10BD09A10BD13A10BH04
AHFS Codes
  • 68:20.05
PDB EntriesNot Available
FDA labelDownload (648 KB)
MSDSDownload (479 KB)
Interactions
Drug Interactions
Drug
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Alogliptin.
AripiprazoleThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Aripiprazole.
Arsenic trioxideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Arsenic trioxide.
ArticaineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Asenapine.
AtazanavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Atazanavir.
BendroflumethiazideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Bendroflumethiazide.
BetamethasoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Betamethasone.
BrexpiprazoleThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Brexpiprazole.
BumetanideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Bumetanide.
BuserelinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Buserelin.
CeritinibThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ceritinib.
ChlorothiazideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorothiazide.
ChlorpropamideAlogliptin may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorthalidone.
ClozapineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Clozapine.
CorticotropinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Cortisone acetate.
Cyproterone acetateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Cyproterone acetate.
DabrafenibThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Dabrafenib.
DanazolThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Danazol.
DarunavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Darunavir.
DesogestrelThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Dexamethasone.
DiazoxideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Diazoxide.
DienogestThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Dienogest.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Alogliptin.
DisopyramideAlogliptin may increase the hypoglycemic activities of Disopyramide.
DrospirenoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Drospirenone.
EpinephrineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Epinephrine.
ErythromycinAlogliptin may increase the hypoglycemic activities of Erythromycin.
EstradiolThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Estradiol.
Estrone sulfateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Estropipate.
Etacrynic acidThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ethacrynic acid.
Ethinyl EstradiolThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ethinyl Estradiol.
Ethynodiol diacetateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ethynodiol.
EtonogestrelThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Etonogestrel.
EverolimusThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Everolimus.
FludrocortisoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Fludrocortisone.
FosamprenavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Fosamprenavir.
FurosemideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Furosemide.
GliclazideAlogliptin may increase the hypoglycemic activities of Gliclazide.
GlimepirideAlogliptin may increase the hypoglycemic activities of Glimepiride.
GlipizideAlogliptin may increase the hypoglycemic activities of Glipizide.
GlyburideAlogliptin may increase the hypoglycemic activities of Glyburide.
GoserelinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin.
HistrelinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Histrelin.
HydrochlorothiazideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydrocortisone.
Hydroxyprogesterone caproateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydroxyprogesterone caproate.
IloperidoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Iloperidone.
IndapamideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Indapamide.
IndinavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Indinavir.
Insulin AspartAlogliptin may increase the hypoglycemic activities of Insulin Aspart.
Insulin DegludecAlogliptin may increase the hypoglycemic activities of Insulin degludec.
Insulin DetemirAlogliptin may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineAlogliptin may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineAlogliptin may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanAlogliptin may increase the hypoglycemic activities of Insulin Regular.
Insulin LisproAlogliptin may increase the hypoglycemic activities of Insulin Lispro.
LanreotideAlogliptin may increase the hypoglycemic activities of Lanreotide.
LeuprolideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Leuprolide.
LevonorgestrelThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Levonorgestrel.
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Alogliptin.
LopinavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Lopinavir.
LurasidoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Lurasidone.
MecaserminAlogliptin may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Medroxyprogesterone Acetate.
Megestrol acetateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Megestrol acetate.
MestranolThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Mestranol.
MethotrimeprazineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methyclothiazide.
MethylprednisoloneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Methylprednisolone.
MetolazoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Metolazone.
MifepristoneAlogliptin may increase the hypoglycemic activities of Mifepristone.
NadololThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Nadolol.
NateglinideAlogliptin may increase the hypoglycemic activities of Nateglinide.
NelfinavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Nelfinavir.
NiacinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Niacin.
NilotinibThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Nilotinib.
NorethisteroneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Norethindrone.
NorgestimateThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Norgestimate.
OctreotideAlogliptin may increase the hypoglycemic activities of Octreotide.
OlanzapineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Olanzapine.
OxandroloneOxandrolone may increase the hypoglycemic activities of Alogliptin.
PaliperidoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Paliperidone.
ParoxetineParoxetine may increase the hypoglycemic activities of Alogliptin.
PasireotideAlogliptin may increase the hypoglycemic activities of Pasireotide.
PegvisomantPegvisomant may increase the hypoglycemic activities of Alogliptin.
PentamidineAlogliptin may increase the hypoglycemic activities of Pentamidine.
PerindoprilThe risk or severity of adverse effects can be increased when Alogliptin is combined with Perindopril.
PhenelzinePhenelzine may increase the hypoglycemic activities of Alogliptin.
PipotiazineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Pipotiazine.
PrednisoloneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Prednisolone.
PrednisoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Prednisone.
ProgesteroneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Progesterone.
QuetiapineThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Quetiapine.
QuinineAlogliptin may increase the hypoglycemic activities of Quinine.
RepaglinideAlogliptin may increase the hypoglycemic activities of Repaglinide.
Repository corticotropinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Repository corticotropin.
RisperidoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Risperidone.
RitonavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ritonavir.
SaquinavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Saquinavir.
SirolimusThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Sirolimus.
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Alogliptin.
SulfadiazineAlogliptin may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleAlogliptin may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleAlogliptin may increase the hypoglycemic activities of Sulfisoxazole.
SunitinibAlogliptin may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Tacrolimus.
TemsirolimusThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Temsirolimus.
TestosteroneTestosterone may increase the hypoglycemic activities of Alogliptin.
TipranavirThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Tipranavir.
TolazamideAlogliptin may increase the hypoglycemic activities of Tolazamide.
TolbutamideAlogliptin may increase the hypoglycemic activities of Tolbutamide.
TorasemideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Torasemide.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Alogliptin.
TriamcinoloneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Triamcinolone.
TrichlormethiazideThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Trichlormethiazide.
TrimethoprimAlogliptin may increase the hypoglycemic activities of Trimethoprim.
TriptorelinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Triptorelin.
VorinostatThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Vorinostat.
ZiprasidoneThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Virus receptor activity
Specific Function:
Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by binding at least ADA, CAV1, IGF2R, and PTPRC. Its binding to CAV1 and CARD11 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Its interaction with ADA also ...
Gene Name:
DPP4
Uniprot ID:
P27487
Molecular Weight:
88277.935 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:17 / Updated on June 29, 2016 01:52